Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab + exemestane in advanced breast cancer
NCT00372996Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Feb 2007
- Primary completion
- Sep 2012
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of figitumumab in breast cancer, sponsored by Pfizer. Started Feb 2007; status: terminated.
02
Drugs
figitumumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00372996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372996.